![Peter Seiler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Seiler
Directeur/Membre du Conseil chez OMEICOS Therapeutics GmbH
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Karen Uhlmann | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 ans |
Robert Fischer | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 ans |
Eckhard Schulte | M | 56 |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Wolf-Hagen Schunck | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 ans |
Christian Schetter | M | 60 |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 5 ans |
Burkhard Dahmen | M | 60 |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Taro Inaba | M | 56 |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Ökonom Torsten Heising | M | - |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Leonardo Caló | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Michael Rzepczyk | M | 58 |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Jürgen Kluge | M | 70 |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Martin Pfister | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Thomas Otto | M | - |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Bernhard Kirschbaum | M | 65 |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Hans Hubert Lienhard | M | 73 |
SMS GmbH
![]() SMS GmbH Industrial MachineryProducer Manufacturing SMS GmbH provides metallurgical plant and rolling mill technology, press and forging technology and plastics technology services. The company was founded in 1819 and is headquartered in Dusseldorf, Germany. | - |
Ute Mercker | F | 58 |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 9 ans |
Gaston Matthyssens | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Andreas Goette | M | - |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Allemagne | 18 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Peter Seiler
- Réseau Personnel